Cambridge, UK-based diagnostics firm Owlstone Medical has added three business development, clinical research and manufacturing executives to its senior management team.
Chris Hodkinson (pictured) becomes vice president of business development, taking on responsibility for the company’s cancer products business operations.
He joins Owlstone Medical from Abcodia, a specialist company focused on developing biomarkers for cancer screening that he co-founded, having most recently served as director and chief operating officer.
Meanwhile Dr Marc van der Schee has been appointed as lead clinical research scientist for the diagnostics firm, with a remit to design and oversee all clinical trials and product development.
He brings 10 years of biomarker research experience to Owlstone Medical, including medical, epidemiological, chemical analytical and data-analysis for which he was awarded a Marie Curie fellowship.
Lastly, Hamilton Scanlon joins the firm as vice president of manufacturing and brings over 30 years of industry experience across China, Italy and the UK to the role.
Scanlon will be tasked with manufacturing the scale-up of Owlstone Medical’s clinical research and development tools used in biomarker discovery.
Billy Boyle, co-founder and chief executive officer of Owlstone Medical, said: “Owlstone Medical was created very specifically to advance our breathalyzer for very early stage diagnosis of disease when it can be treated more effectively for better patient outcomes.
“We are excited to see the company expanding so soon after being spun-out, and are confident that Chris, Marc and Hamilton will be great assets to the team.”